The Antibody Series 2026
The 6th edition of The Antibody Series took place in Évora, Portugal. The 2026 scientific agenda was chaired by Laura Walker and John Desjarlais and included special Keynotes and themes such as Lessons from Natural Antibody Repertoires, Harnessing Multispecificity to Drive Novel Functions, Computational Antibody Design, Emerging Antibody Based Therapies in Autoimmune Diseases and Engineering Agonism.
Gallery
2026 Speakers
Associate Professor (since 2018) at ETH Zurich in the Department of Biosystems Science and Engineeri
Sarel Fleishman is a Professor at the Weizmann Institute of Science and Chief Scientist at Scala Bio
Dr Jo Viney,Ph.D. is co-founder, President and CEO of Seismic Therapeutic
Mark Cragg is Professor of Experimental Cancer Biology in the School of Cancer Sciences at the Unive
Surge Biswas is a co-founder the CEO at Nabla Bio
Dr. Lazar is Co-Founder and Chief Scientific Officer at Dualitas Therapeutics
George Georgiou is the Dula D. Cockrell Centennial Chair and Professor at UT Austin
Dr. Wyatt McDonnell is Co-Founder and CEO of Infinimmune, a preclinical antibody biotechnology comp
Anna Wec is an Associate Director in Infectious Disease Research at Moderna, where she leads antibod
Dr. Robert A. Seder is currently Acting Associate Director and Chief of the Cellular Immunology Sect
Co-founder and Executive Vice President of Technology and Scientific Office at FairJourney Bio
Senior Director of Biologics at Xilio Therapeutics, where he leads antibody discovery, in silico bio
Melissa Geddie, Ph.D., is the SVP of Drug Discovery at Diagonal Therapeutics.
Joanne Hulme Ph.D., currently is the Chief Scientific Officer of Radiant Biotherapeutics.
Aneesh Karatt-Vellatt, PhD is Chief Scientific Officer and Co-Founder at Maxion Therapeutics
Karyn O’Neil is the Chief Scientific Officer and Co-Founder at Aro Biotherapeutics